Relationship between Sustained Disability Progression and Functional System Scores in Relapsing-Remitting Multiple Sclerosis: Analysis of Placebo Data from Four Randomized Clinical Trials

2015 ◽  
Vol 44 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Thomas Scott ◽  
Ping Wang ◽  
Xiaojun You ◽  
Monica Mann ◽  
Bjørn Sperling

Background: The Expanded Disability Status Scale (EDSS), based on different functional system scores (FSS), remains the most frequently used disability assessment in relapsing-remitting multiple sclerosis (RRMS). In this analysis, we evaluated the relationship between sustained disability progression, measured by EDSS, and simultaneous changes in individual FSS domains. Methods: A post hoc analysis was performed on data from placebo-treated RRMS patients from four large, randomized, multicenter, phase 3 clinical trials. Sustained disability progression was defined as a ≥1.0-point EDSS score increase over a ≥3- or ≥6-month period. Simultaneous sustained disability progression and worsening of individual FSS domains was analyzed. Results: The majority of patients experienced sustained disability progression and simultaneous worsening of ≥1 FSS domain, with ≥1-point worsening in the pyramidal domain being most frequently associated with sustained disability progression (in 31-51% of patients), followed by ≥1-point worsening in the cerebellar (35-41% of patients) and sensory (31-45% of patients) domains. Conclusion: The key FSS components correlating with sustained disability progression, measured by EDSS, appear to be pyramidal, cerebellar, and sensory. In this analysis, the simultaneous worsening of consistent FSS domains confirms the validity and reliability of the use of sustained EDSS progression as a measure of disability progression.

2020 ◽  
Vol 267 (12) ◽  
pp. 3753-3762
Author(s):  
Anat Achiron ◽  
◽  
Alon Ben-David ◽  
Michael Gurevich ◽  
David Magalashvili ◽  
...  

2013 ◽  
Vol 115 ◽  
pp. S65-S69 ◽  
Author(s):  
Jelena Drulovic ◽  
Jelena Kostic ◽  
Sarlota Mesaros ◽  
Irena Dujmovic Basuroski ◽  
Nebojsa Stojsavljevic ◽  
...  

2014 ◽  
Vol 20 (12) ◽  
pp. 1602-1608 ◽  
Author(s):  
Jordi Río ◽  
Alex Rovira ◽  
Mar Tintoré ◽  
Jaume Sastre-Garriga ◽  
Joaquín Castilló ◽  
...  

Background: In patients with relapsing–remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA). Objective: The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA. Methods: This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables. Results: The total possible score range was 0–3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively). Conclusions: In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.


Sign in / Sign up

Export Citation Format

Share Document